Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose intravenous adenosine during primary PCI for acute myocardial infarction
NL-OMON23567Active, not recruiting
- Sponsor
- Medisch Spectrum Twente
- Start
- Sep 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of adenosine in myocardial infarction (MI), sponsored by Medisch Spectrum Twente. Primary endpoints: Infarct size on contrast-enhanced MRI and No-reflow zone on contrast-enhanced MRI. Started Sep 2008; status: active, not recruiting.
02
Drugs
adenosine
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON23567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23567.